lamivudine / Generic mfg. - LARVOL DELTA

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study (ASH 2025) - "All HBV-positive patients received prophylactic antiviral treatment, predominantly with lamivudine (>90%)...Axi-cel was the most frequently used CAR-T product (53.5%), followed by tisa-cel (32.8%), brexu-cel (12.6%), and liso-cel (1.2%)...The lower incidence of CRS and milder ICANS severity observed in HBV-positive patients may point to potential immunomodulatory effects exerted by OBI status and/or antiviral prophylaxis. Systematic HBV screening and appropriate antiviral prophylaxis remain essential to minimize the rare risk of viral reactivation."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma

Mutant megakaryocytes orchestrate marrow immune remodeling via inflammatory and LINE‑1–Driven mechanisms in MPNs (ASH 2025) - "Single-cell RNA-sequencing (scRNAseq) on unfractionated marrow cells from young (4mo old) andaged (1yr old) Pf4‑cre⁺FF1⁺ and control mice revealed that aging amplifies JAK2V617F mutant MK–drivenimmune modeling...Lamivudine treatment reduced LINE‑1 RNA in mutant MKs,implicating retrotransposition...In MPNs,JAK2V617F mutation and aging synergistically enhance MK-mediated inflammatory andimmunoregulatory functions. The discovery of elevated LINE‑1 activity in aged mutant MKs linksretrotransposon biology to innate immune activation and chronic inflammation, providing a novelmechanism by which diseased MKs reshape the marrow environment to favor mutant clonal expansionand potentially accelerat MPN progression."

Hematological Disorders • Myeloproliferative Neoplasm • Orthopedics • CD8 • IL1B • ITGA2B • STING • TGFB1

A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens. (PubMed, J Antimicrob Chemother) - "Safety and effectiveness of TLD dose reduction strategies can only be established in clinical studies and cannot be extrapolated from models. However, these models can inform regimen design to limit the window of opportunity for emergence of resistance, i.e. where viral replication occurs in the presence of appreciable drug concentrations."

Journal

Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study. (PubMed, EClinicalMedicine) - P2 | "Participants were centrally randomised to receive once-daily oral GSK'254 100 (N = 22), 150 (N = 20), or 200 mg (N = 22) or lamivudine (3TC) 300 mg (double-blinded dose) (N = 21), all with open-label DTG 50 mg. GSK'254 plus DTG demonstrated generally comparable efficacy and safety to DTG plus 3TC, supporting potential further evaluation of maturation inhibitors for HIV-1 treatment. ViiV Healthcare."

Journal • P2b data • Human Immunodeficiency Virus • Infectious Disease • CD4

Hearing Measures in Children Perinatally HIV-exposed and Uninfected in the PHACS SMARTT Study. (PubMed, Pediatr Infect Dis J) - "While SNHL was relatively common, there were no consistent associations between in utero ARV exposure and SNHL or incomplete DPOAEs. Further research is needed on ARV exposures and other hearing measures in CHEU."

Journal • Human Immunodeficiency Virus • Infectious Disease • Otorhinolaryngology

Different nucleos(t)ide analogs in resected hepatitis B virus-associated hepatocellular carcinoma: a systematic review. (PubMed, Front Pharmacol) - "Compared with the control group, antiviral therapies using telbivudine (HR [95% CrI] = 0.23 [0.12,0.44]), tenofovir disoproxil fumarate (HR [95% CrI] = 0.40 [0.30,0.52]), lamivudine (HR [95% CrI] = 0.50 [0.34, 0.75]), adefovir (HR [95% CrI] = 0.55 [0.38,0.79]), and entecavir (HR [95% CrI] = 0.55 [0.43,0.71]) significantly improved OS...When compared to other nucleos(t)ide analogs, telbivudine and tenofovir disoproxil fumarate exhibited the most notable effects. Identifier CRD42024612794."

Journal • Review • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Oncology • Solid Tumor

Suppression of reverse transcription of retroelements by lamivudine attenuates innate immunity and alleviates rheumatoid arthritis in mice. (PubMed, Int Immunopharmacol) - "In summary, our results indicate that 3TC mitigates RA pathology by blocking reverse transcription of endogenous retroelements and attenuating endogenous retroelement-driven innate immune signaling. Pharmacological inhibition of retroelements thus represents a promising therapeutic approach for RA."

Journal • Preclinical • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CSF1

Retroelements in thyroid cancer: epigenetic plasticity, dedifferentiation, and therapeutic opportunities. (PubMed, Rev Endocr Metab Disord) - "Emerging data also indicate that reverse transcriptase inhibitors (e.g., lamivudine, nevirapine) can partially suppress retroelement activity, induce transcriptional reprogramming and restore radioiodine uptake in refractory thyroid tumors, highlighting a potential therapeutic vulnerability. By integrating cancer epigenetics and mobilome biology, this review reframes thyroid tumor evolution as a process shaped not only by genetic alterations but also by retroelement-mediated disruption of genome regulation. Retroelements may serve as biomarkers of aggressive transformation and as actionable targets in translational oncology."

Journal • Review • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma • BRAF • TERT • TP53

Machine Learning-Based Prediction of Decompensation in Hepatitis B Virus-Related Cirrhosis. (PubMed, Diagnostics (Basel)) - "The use of two antiviral drugs were considered: entecavir (ETV) and lamivudine (LAM)... ML-based prediction of decompensation using electronic health records may assist clinicians in decision making. Findings of this study also underline the impact of antiviral therapy as a key predictor for decompensation."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=28 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial primary completion date: Oct 2025 ➔ Jul 2026

Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Repurposing Lamivudine: A novel therapeutic strategy for ischemic stroke targeting the glycolytic enzyme Pgk1. (PubMed, Biochem Pharmacol) - "Moreover, overexpression of Pgk1 by Adeno-Associated Virus (AAVs) reduced the neuronal deficits, cerebral infarction volumes, and histopathology changes in the rats experiencing cerebral ischemia-reperfusion (I/R) injury. In summary, lamivudine stimulates Pgk1 to enhance the critical survival pathway to ramp down both apoptosis and pyroptosis to improve ischemic stroke, that would facilitate translation of lamivudine into new medicine against the fatal disease."

IO biomarker • Journal • Cardiovascular • CNS Disorders • Ischemic stroke • Reperfusion Injury • BCL2 • PGK1

Molecular imprinted solid-phase extraction and analysis of Entecavir in presence of its induced degradation products and co-administered drug(s) in spiked human plasma, environmental three-color assessment and sustainability profiling. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "MISPE was also used for the extraction of ETV from spiked human samples containing the co-administered drug lamivudine. The proposed method transcended in saving energy, efficiency and applicability. The sustainability profile for the proposed method was established using the efficient-valid-green (EVG) framework displayed via its radar chart, that showed balance between the three pillars, and the NQS index that displays the excellent alignment of the method with the UN-17 SDGs."

Journal

Anti-inflammatory effect of lamivudine on ulcerative colitis. (PubMed, Biochem Biophys Rep) - "Additionally, lamivudine significantly down-regulated the expression of the inflammatory factors IL-6, IL-17, and TNF-α in intestinal tissues and concomitantly up-regulated the expression of the anti-inflammatory factor IL-10. Lastly, lamivudine significantly attenuated the symptoms of colitis and the level of intestinal inflammation in mice and exerted anti-inflammatory effects."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL10 • IL17A • IL6 • TNFA

Quality by digital design in action: a workflow for crystallisation and isolation. (PubMed, Int J Pharm) - "This study uses three exemplar compounds (ibuprofen, lamivudine, and AZD0837), each of which presents a different challenge for crystallisation; these include agglomeration, solid state form, and slow growth rates, respectively. By exploiting digital tools for process simulation and optimisation, the workflow improves efficiency, even in complex cases where multiple workflow iterations are required. This workflow, therefore, paves the way for more sustainable and cost-effective API production and it promotes future standardisation of digital design in pharmaceutical development."

Journal

Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083. (PubMed, Open Forum Infect Dis) - "HIV phenotyping confirmed that the transmitted virus had DTG and 3TC resistance but retained susceptibility to DTG at higher drug concentrations. Pharmacologic testing indicated that the DTG concentrations observed in this case were sufficient to overcome the effects of 2 major baseline INSTI resistance mutations (G140S and Q148H)."

Journal • Human Immunodeficiency Virus • Infectious Disease

Drug-Induced Vanishing Bile Duct Syndrome: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) Database (ACG 2025) - "A total of 899 cases of VBDS were reported to the FAERS from 2003-2024. 893 were characterized as severe, including 166 deaths (18.6%). The most common reported drugs were – Ibuprofen (11.12%; ROR: 32.35 [26.28, 39.83]; p< 0.05), Sulfamethoxazole/Trimethoprim (9.12%; ROR: 63.23 [50.38, 79.37]; p< 0.05), Ciprofloxacin (7.00%; ROR: 37.87 [29.31, 48.92]; p< 0.05), Lamivudine with and without Zidovudine (6.1%; ROR: 59.38 [45.2, 78.02]; p< 0.05), Azithromycin (5.5%; ROR: 59.21 [44.51, 78.78]; p< 0.05), Temozolomide (5.12%; ROR: 66.57 [49.47, 89.59]; p< 0.05), Nevirapine (4.89%; ROR: 117.62 [86.83, 159.33]; p< 0.05), Levofloxacin (4.67%; ROR: 25.06 [18.39, 34.17]; p< 0.05), Acetaminophen (4.67%; ROR: 9.14 [6.7, 12.46]; p< 0.05), Levetiracetam (4.67%; ROR: 19.02 [13.95, 25.93]; p< 0.05), Lamotrigine (4.00%; ROR: 15.64 [11.2, 21.82]; p< 0.05), and Prednisone (3.78%; ROR: 6.72 [4.77, 9.47]; p< 0.05). Ibuprofen was the most reported drug as a..."

Adverse events • Cholestasis • Hepatology

Exploratory analysis of lamivudine legacy and clonal selection of HBs truncation mutants in HBV-related hepatocellular carcinoma. (PubMed, Infect Agent Cancer) - "While high-barrier NAs like entecavir effectively suppress viral replication, they do not eliminate transcriptionally active HBV integrants...Nevertheless, the results highlight the relevance of antiviral treatment history in shaping HBV mutational profiles and raise the possibility that integrant-derived HBs truncation variants could serve as biomarkers for HCC risk stratification. Early detection of such variants may help refine surveillance strategies in virally suppressed patients and inform future therapeutic approaches."

Journal • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Oncology • Solid Tumor

Sophora alopecuroides biflavones glycoside, isolated from Sophora alopecuroides, inhibits the secretion of hepatitis B virus surface antigen through direct interaction with its antigenic loop domain. (PubMed, Virol J) - "Our studies reveal that SABG exhibits an antiviral activity against HBV by directly binding to the antigenic loop of surface protein, thereby impeding its secretion, which provides pharmacological evidence for the potential use of SABG as a candidate for the alternative treatment of HBV infection."

Journal • Hepatitis B • Infectious Disease • Inflammation

Human Immunodeficiency Virus and Hepatitis B Virus Co-infection in Pregnancy: A Review. (PubMed, Curr HIV/AIDS Rep) - "Guidelines have been revised to reflect the most recent evidence published on the safety and efficacy of both dolutegravir and tenofovir alafenamide in pregnancy...Recent advances in our understanding of the safety profile and efficacy of tenofovir disoproxil/alafenamide and dolutegravir has resulted in these being recommended as first line antiretrovirals, alongside Lamivudine, for HIV/HBV co-infection in pregnancy in United Kingdom, European and the United States guidelines. Appropriate antiretroviral therapy in pregnancy, along with prompt treatment of the neonate, combine to ensure very low rates of perinatal transmission of both HIV and HBV."

Journal • Review • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Obstetrics

A challenging diagnosis of VEXAS syndrome in a person living with HIV: a case of recurrent systemic inflammation and cytopenia (EACS 2025) - "Case Presentation: A 63-year-old male with a history of deep vein thrombosis and HIV diagnosis receiving bictegravir/emtricitabine/tenofovir alafenamide presented with elevated C-Reactive Protein (CRP) and unintentional weight loss...Antiretroviral therapy was switched to lamivudine and dolutegravir with dose adjustment... This case highlights the diagnostic complexity of the rare VEXAS syndrome, particularly in people living with HIV, where overlapping symptoms may initially be misattributed, potentially delaying diagnosis. Table 1 Table 2"

Clinical • Human Immunodeficiency Virus • Infectious Disease • CRP

Antiretroviral Switch and Weight Gain: Cardiometabolic Implications of Switching to Darunavir/Cobicistat + Lamivudine (EACS 2025) - "We included males aged >18 years with adquire HIV, virological suppression for ≥6 months, and on a regimen of darunavir/cobicistat (DRV/c) plus tenofovir/emtricitabine (TDF/FTC). No significant changes in cardiovascular risk were observed. Metabolic alterations should be considered when selecting an antiretroviral regimen."

Human Immunodeficiency Virus • Infectious Disease

Would infant lamivudine prophylaxis during breastfeeding be an option to prevent from vertical transmission of HIV ? (EACS 2025) - P3 | "Children received either a lopinavir/ritonavir (LPV/r)-based regimen (n=92) for a median of 8.0 [3.1-11.0] months, or 3TC monotherapy (n=115) for a median of 10.5 [10.1-11.3] months. Conclusions : These findings suggest that the M184V variant is rare among African mothers, including those on ART, and that 3TC is a viable prophylaxis option to protect against vertical transmission, given its excellent safety profile, ease of administration, good palatability, and evidence of efficacy. Our findings can be applied to all breastfeeding mothers, including African migrant mothers in Europe."

Human Immunodeficiency Virus • Infectious Disease

A diagnostic and therapeutic odyssey in advanced HIV: disseminated tuberculosis with hematologic and renal involvement (EACS 2025) - "Antiretroviral therapy (tenofovir alafenamide/emtricitabine/bictegravir) and trimethoprim-sulfamethoxazole prophylaxis were initiated...Quadruple anti-TB therapy was started, and ART was adjusted to tenofovir disoproxil fumarate, emtricitabine, and twice-daily dolutegravir due to rifampicin interaction...ART was modified to lamivudine and double-dose dolutegravir; ramipril was added... This case underscores the high risk of disseminated TB and adverse outcomes in patients with late HIV diagnosis. Early screening and timely management are critical in high-burden settings such as Türkiye."

Metastases • Human Immunodeficiency Virus • Infectious Disease • Septic Shock • Tuberculosis • CD4

LINE-1 retrotransposon activation drives age-associated inflammation via cytoplasmic cDNA-STING/type I interferon signalling: therapeutic potential of reverse transcriptase inhibition. (PubMed, Contemp Oncol (Pozn)) - "Activation of retrotransposons is a key factor in sterile inflammation, which is a hallmark of aging, and LINE-1 reverse trans-criptase is an important target for the treatment of age-associated diseases. Nucleoside reverse transcriptase inhibitor lamivudine downregulates activation of type-I interferon and age-associated inflammation."

Journal • Review • Inflammation • STING

The efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in treatment-naïve and treatment-experienced patients with HIV. (PubMed, Ann Med) - "Twenty-seven patients (32.5%) were treatment-naïve PWH, and 56 patients (67.5%) were treatment-experienced PWH, the most common switch was from integrase inhibitors (37/56) to DOR, followed by efavirenz (18/56) and nevirapine (1/56). In addition, anxiety, depression and sleep disorders improved in those patients who switched regimens from efavirenz to DOR. We provide a short-term observational report of the efficacy and safety of DOR/3TC/TDF in routine clinical practice, further supporting its use in PWH."

Journal • Retrospective data • CNS Disorders • Depression • Human Immunodeficiency Virus • Infectious Disease • Mood Disorders • Psychiatry • Sleep Disorder • CD4